Alzheimer's Disease clinical trials at University of California Health
51 in progress, 24 open to eligible people
[18F]PI-2620 Phase 3 Histopathological Study
open to eligible people ages 50 years and up
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime …
at UCLA
AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
open to eligible people ages 50-80
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's…
at UCSD
Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
open to eligible people ages 18 years and up
This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, …
at UCLA UCSD
Senicapoc in Alzheimer's Disease
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 55-85
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small…
at UC Davis
Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
open to eligible people ages 50-89
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
at UC Irvine
Biomarker Exploration in Aging, Cognition and Neurodegeneration
open to eligible people ages 60 years and up
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain…
at UC Irvine
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
open to eligible people ages 50-83
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
at UCSD
Cardiac-Control Affecting Learning Through Mindfulness (CALM)
open to eligible people ages 50-70
Some types of meditation lead heart rate to become more steady as breathing quiets whereas others lead to large heart rate swings up and down (oscillations) as breathing becomes deeper and slower. The current study is designed to investigate how…
at UC Irvine
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
open to eligible people ages 60-100
The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work…
at UCLA
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
open to eligible people ages 18-80
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug…
at UCSD
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
open to eligible people ages 40-75
This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in…
at UCSF
Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
open to eligible people ages 65-85
Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. …
at UCSD
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
open to eligible people ages 50-90
The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild…
at UCLA
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
open to eligible people ages 50-90
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
at UCLA
Music, Social Attention, and Dementia
open to eligible people ages 55-89
This is an exploratory mixed-methods control-treatment study to evaluate if participation in rhythmic musical activities improves social attention and connectedness in individuals living with mild to moderate bvFTD and AD, and their caregivers.…
at UCSF
Promoting Physical Activity in Older Hispanic/Latino(a) Adults
open to eligible people ages 55-89
In this randomized controlled trial, study staff will randomize 130 Hispanic/Latino adults without dementia and over age 55 from Southern California and from Kaiser Permanente Washington (State) to either the culturally adapted De Pie physical…
at UCSD
PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
open to eligible people ages 18-80
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of…
at UCSF
Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
open to eligible people ages 60-80
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
at UC Davis UCSF
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
open to eligible people ages 60 years and up
The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early…
at UCSD
Alzheimer's Disease Neuroimaging Initiative 4
open to eligible people ages 55-90
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2,…
at UC Davis UC Irvine UCLA UCSD UCSF
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
open to eligible people ages 18 years and up
The investigators are researching families with inherited inclusion body myopathy (IBM) and/or Paget disease of bone (PDB) and/or dementia (FTD) which is also called IBMPFD. IBMPFD is caused by mutations in the VCP gene. Our main goal is to…
at UC Irvine
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
open to eligible people ages 65 years and up
The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally…
at UCSF
Longitudinal Early-onset Alzheimer's Disease Study Protocol
open to eligible people ages 40-64
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging,…
at UCLA UCSF
Trial-Ready Cohort-Down Syndrome (TRC-DS)
open to eligible people ages 25-55
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 450 participants in total including co-enrolled in the…
at UC Irvine
Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Sorry, in progress, not accepting new patients
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which…
at UCLA
Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Sorry, not currently recruiting here
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will…
at UCSD
Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Sorry, in progress, not accepting new patients
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered…
at UCSF
E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Sorry, not currently recruiting here
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in…
at UCSF
JNJ-63733657 in Participants With Early Alzheimer's Disease
Sorry, in progress, not accepting new patients
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
at UCLA UCSD
Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Sorry, not currently recruiting here
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug…
at UCSD
Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Sorry, in progress, not accepting new patients
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum …
at UCLA UCSF
Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Sorry, in progress, not accepting new patients
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow…
at UCLA UCSD UCSF
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Sorry, in progress, not accepting new patients
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine…
at UC Davis UC Irvine UCSF
Alzheimer's Tau Platform: Master Protocol
Sorry, not yet accepting patients
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This…
at UCSF
Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention
Sorry, in progress, not accepting new patients
The purpose of this research is to determine if training in memory support aids and healthy lifestyle activities (physical exercise, mentally stimulating activities and stress management) can have a positive effect on memory, thinking, and…
at UC Davis
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Sorry, in progress, not accepting new patients
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related…
at UCSD
Epileptic Hippocampus in Alzheimer's Disease
Sorry, not yet accepting patients
The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB …
at UCLA
Escitalopram for Agitation in Alzheimer's Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
at UCLA
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical…
at UCSF
Metformin in Alzheimer's Dementia Prevention
Sorry, in progress, not accepting new patients
MAP will be a multisite phase II/III 1:1 randomized controlled trial (RCT) of long acting metformin (reduced mass Glucophage XR) vs. matching placebo in 326 men and women with early and late aMCI, without diabetes, not treated with metformin,…
at UC Irvine
Brain Health Study: A Pragmatic, Patient-Centered Trial
Sorry, in progress, not accepting new patients
The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.
at UCSF
Care Ecosystem Consortium Effectiveness Study
Sorry, in progress, not accepting new patients
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by…
at UCLA UCSF
Digital Memory Notebook
Sorry, accepting new patients by invitation only
Compensatory aids (e.g., alarms, calendars) play an important supporting role when completing everyday tasks (e.g., appointments, medication management), and there is a growing body of scientific work suggesting that compensatory training improves…
at UC Davis
Diagnostic Test for Dementia With Lewy Bodies
Sorry, in progress, not accepting new patients
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
at UCSD
Alzheimer's Plasma Extension
Sorry, accepting new patients by invitation only
The APEX study is a multicenter, observational study designed to capture longitudinal follow-up of plasma biomarkers and cognitive and functional assessments on individuals who screen failed in the AHEAD study over approximately 4 years.…
at UC Davis UC Irvine UCSF
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Sorry, accepting new patients by invitation only
Years before someone experiences the symptoms of Alzheimer's disease, a compound called amyloid beta (Aβ) builds up in the brain. Excess Aβ - directly or indirectly - causes many of the symptoms of Alzheimer's dementia. However, recent studies of…
at UC Davis
Environmental and Reproductive Health Risk for Lewy Body Dementia
Sorry, in progress, not accepting new patients
The goal of this survey study is to identify environmental, occupational and reproductive health risk factors for Lewy body dementia, which includes Parkinson's disease dementia and dementia with Lewy bodies. Participants will complete a one-time…
at UCSD
Living Alone in Old Age With Cognitive Impairment
Sorry, in progress, not accepting new patients
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment. This…
at UCSF
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
Sorry, in progress, not accepting new patients
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association.…
at UCSF
Diabetes Prevention Program Outcomes Study AD/ADRD Project
Sorry, accepting new patients by invitation only
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment…
at UCLA UCSD
DIAGNOSE CTE Research Project-II
Sorry, accepting new patients by invitation only
Each year, millions of people are exposed to repetitive head impacts (RHI) through contact sports. RHI can result in concussions and asymptomatic non-concussions to confer risk for Alzheimer's disease (AD) and related dementias (ADRD) including…
at UCSF
Our lead scientists for Alzheimer's Disease research studies include Scott Mackin, Ph.D. Atul Malhotra Doug Galasko Sarah Farias, PhD Neal Swerdlow, M.D., Ph.D. Mark Tuszynski, M.D., Ph.D. Paula Desplats, PhD Daniel H. Silverman, MD, PhD Susan Y. Bookheimer, PhD Deborah Barnes, PhD Elena Portacolone, PhD MPH MBA Katherine L Possin, PhD Mario F. Mendez, MD, PhD Michael A Yassa, PhD David Wilson, MD, PhD Virginia Kimonis, MD Marie Kim, MD, PhD Keith A Vossel, MD, MSc Aaron Colverson, PhD Zvinka Z Zlatar, PhD Vinil Shah John Olichney, MD Pauline Wu, DO.
Last updated: